Navigation Links
Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine ,,, in Bovine Plasma using the TSQ Quantum Mass Spectrometer

Mark Churchill and Mark Harrison, Thermo Finnigan, Hemel Hempstead, UK

Bioanalytical Method Validation

The data presented here can be acquired using a Thermo Finnigan TSQ Quantum mass spectrometer Introduction Guidelines on Bioanalytical Method Validation acceptance criteria were established by the US Food and Drug Administration (FDA) from a conference on Analytical Methods Validation Bioavailability, Bioequivalence and Pharmacokinetic Studies held in Arlington,VA, December 3-5, 1990.1 These acceptance criteria were reviewed ten years on at Bioanalytical Methods Validation A Revisit with a Decade of Progress, Arlington,VA, January 12-14, 2000,2 a meeting sponsored by the American Association of Pharmaceutical Scientists and the FDA. This led to the issue of the FDA Guidance for Industry document on Bioanalytical Method Validation in May 20013. A full method validation should assess accuracy, precision, selectivity, sensitivity, reproducibility and stability of an analyte in matrix samples.

Paroxetine is an orally administered antidepressant which acts as a selective serotonin reuptake inhibitor (SSRI) but has only minimal effects on the neuronal reuptake of norepinephrine and dopamine. Paroxetine is administered for the treatment of depression, social anxiety disorder, obsessive compulsive disorder, panic disorder and generalized anxiety disorder. Goal This report describes the ease of use of the TSQ Quantum to validate bioanalytical methods in accordance with the guidelines issued by the US Food and Drug Administration.

The aim of this investigation was to demonstrate the sensitivity, linearity, and robustness of the TSQ Quantum to allow researchers to achieve excellent accuracy and precision for highthroughput quantitation of analytes in biological matrices. Paroxetine spiked into bovine plasma was injected as an intra-day batch consisting of blanks, calibration standards, and QCs at eight replicates. TSQ Quantum Tune View Optimization of Paroxetine Paroxetine (C19H20FNO3, molecular weight 329.37) was infused, 0.1 ng/L, into the ESI source and the four most abundant product ions for the MS/MS breakdown were determined using the automated compound optimization procedure in the TSQ Quantum (Figure 1).

The transition yielding the most abundant product ion (m/z 192.1) was used for the analysis of Paroxetine. Figure 1: Automated optimization of MS/MS parameters for Paroxetine Experimental Conditions Sample Preparation: Aliquots (1 milliliter) of Bovine Plasma (Sigma P4639) were spiked with Paroxetine (Figure 2) in the concentration range of 0.1, 0.2, 0.5, 1, 2, 5, 10, 50, 100, 200, 500 and 1000 pg/L for the calibration standards and at levels of 0.3, 25 and 750 pg/L for quality control samples. De-Fluoro-Paroxetine (Internal Standard, Figure 3) was spiked at a concentration of 25 pg/L. Blank Bovine plasma and plasma containing internal standard were also prepared. Eight replicate plasma aliquots of 100 L were taken from each spiked level and protein precipitated using 250 L of Acetonitrile, centrifuged at 13,000 rpm for 10 minutes and the supernatants decanted. The extracts were evaporated under a stream of nitrogen gas and reconstituted in 100 L of Water/Methanol/Acetic acid (80/20/0.1 v/v/v).

Sample Analysis: The plasma extracts were chromatographed (Thermo Finnigan Surveyor System) on a C18 Elite 100 mm 2.1 mm column (Thermo Hypersil-Keystone) at a flow rate of 250 L/min with a linear gradient of 10% Solvent B (methanol containing 0.1% acetic acid) to 95% B over five minutes. Solvent A was water containing 0.1% acetic acid. Injection volumes of 10 L were used. MS Conditions: Mass spectrometer: Thermo Finnigan TSQ Quantum
Ionization mode: Electrospray (ESI), positive ion
Resolution: 0.7 Dalton Full Width Half Maximum on Q1 and Q3
Selected Reaction Monitoring:
Paroxetine 330.20 > 192.1 +/- 0.3 Da, 22 V collision energy
De-Fluoro-Paroxetine 312.20 > 174.1 +/- 0.3 Da, 20 V collision energy
Argon collision gas pressure 1.5 mTorr

Figure 2: Paroxetine

Figure 3: De-Fluoro Paroxetine

LC/MS/MS Chromatograms of Bovine Plasma Spiked with Paroxetine and Internal Standard Blank Plasma,Plasma containing Internal Standard,Calibration Standards at 0.1 and 0.5 pg/L Figure 4a: Blank Plasma
Figure 4b: Plasma containing Int Std


Figure 4c: Plasma spiked at 0.1 pg/L
Figure 4d: Plasma spiked at 0.5 pg/L
LC/MS/MS Chromatograms of Bovine Plasma Spiked with Paroxetine and Internal Standard Quality Control samples at 0.3 and 25 pg/L Figure 5a: Quality Control at 0.3 pg/L

Figure 5b: Quality Control at 25 pg/L Results The chromatography (Figure 4a4d and 5a5b) was capable of resolving Paroxetine and De-Fluoro-Paroxetine from any matrix peaks and was suitable for the quantitation of unknowns.

A calibration curve was constructed from the first and eighth replicate set of calibration standards (Figure 6). The linear fit calibration curve, weighted 1/X, of area ratio plotted against concentration was used to calculate the concentrations of all calibration standards and quality control samples throughout the analytical batch.

A correlation coefficient of r2=0.9994 with an equation of Y=0.00346891 +0.0312025*x was obtained for the curve.

The internal standard peak area response was 3.1% cv for 121 injections (Figure 7). Figure 6: Paroxetine/Int Std area ratio

Figure 7: Internal Standard area response The calibration curve was used to calculate the values of the eight replicates at each level of quality control sample (Table 1) and of the remaining six replicates of standards (Table 2). Table 1: Intra-batch accuracy and precision of quality control data for Paroxetine in Bovine plasma

Table 2: Intra-batch accuracy and precision of calibration data for Paroxetine in Bovine Plasma
*Calibration data sets 1 and 8 used to construct curve Discussion The lowest calibration standard selected for this assay at 0.1 pg/L had a minimum signal-to-noise of greater than 5:1 and variability of 3% from eight determinations. This was well within the acceptance criteria set by the guidelines which defines that the Limit of Quantitation (LOQ) of an assay should have less than 20% variability.

The Intra-batch variability of back-calculated concentrations of Paroxetine in Bovine Plasma was less than 3% across the whole calibration range. This falls well within the expected method validation acceptance criteria as set by Shah et al of 20% variability at the LOQ and less than 15% variability at all other concentrations of the calibration standards.

The validated method accuracy and precision were determined from the backcalculated values of the Quality Control samples. The intra-batch accuracy was 103.6%, 104.0% and 99.7% at concentrations of 0.3, 25 and 750 pg/L respectively. The intra-batch precision was 2.2%, 0.6% and 0.6% at concentrations of 0.3, 25 and 750 pg/L respectively.

The validation data indicate that the TSQ Quantum is sensitive, robust and linear (four orders of dynamic range demonstrated here) and is an ideal instrument for the quantitation of analytical substances in Biological matrices. References 1 Shah, V.P., et al, Pharmaceutical Research, Vol 9, No 4, 588-592, 1992
2 Shah, V.P., et al, Pharmaceutical Research, Vol 17, No 12, 1551-1557, 2000
3 Guidance for Industry, Bioanalytical Method Validation, U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), May 2001
'"/>

Source:


Page: All 1 2 3 4 5 6

Related biology technology :

1. A New PCR-based Mycoplasma Detection Method
2. DNA-free A NEW Method to Remove DNA
3. RNase Activity in Mouse Tissue: Classification, Hierarchy, and Methods for Control
4. Comparison of Different Methods of mRNA Quantitation
5. Rapid Method Development With the BioLogic DuoFlow Chromatography System for the Purification of His-Tagged Proteins
6. A Rapid Method for the Purification of Analytical Grade Proteins From Plants Using Preparative SDS-PAGE and Preparative IEF
7. Comparison of PCR Kleen Spin Columns to Traditional Methods for Purification of PCR Products Prior to Sequencing, Rev A
8. Commercial Plasmid Preparation Methods Yield DNA With Different Transfection Capabilities
9. Bio-Plex Cytokine Immunoassays and ELISA: Comparison of Two Methodologies in Testing Samples From Asthmatic and Healthy Children, Rev A
10. A Rapid Method for the Purification of Analytical Grade Proteins From Plants Using Preparative SDS-PAGE and Preparative IEF
11. A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders
Post Your Comments:
(Date:10/25/2014)... -- RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" or "RegeneRx") ... Symposium on Thymosins in Health and Disease in ... thymosin beta 4 (TB4) linked with rhodamine (a fluorescent ... a rodent model of stroke, it was visualized outside ... functional tissue of the brain).   The leakage of TB4 ...
(Date:10/22/2014)... -- Research and Markets has announced ... Market (Product types, Application, Technology, End User and ... Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and ... offering. This new report titled, ... and Geography) Global Size, Industry Analysis, Trends, Opportunities, ...
(Date:10/22/2014)... Involution Studios , a healthcare ... new infographic, Understanding Ebola . The goal ... easy to follow informative tool for anyone wanting to ... and prevention. , "As the news has spread in ... outbreak represents not only a healthcare crisis with global ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 According ... Market by Service Type (Consulting, Integration, Deployment & ... by Deployment Model (Public, Private, Others (Hybrid & ... MarketsandMarkets, defines and segments the Cloud Professional Services ... and forecasting of revenues. It also identifies the ...
Breaking Biology Technology:Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5
... Medarex, Inc. (Nasdaq: MEDX ) announced today ... J.P. Morgan Healthcare Conference at 8:30 a.m. Pacific Time (11:30 ... will be webcast live and will be available in the ... . An archived edition of the presentation will be available ...
... PCYC ) today announced that in ... Associates ("RWD") made an unsecured loan to,Pharmacyclics, Inc. ... $5,000,000. As of,December 31, 2008, the company,s ... the $5,000,000 in loan proceeds. RWD,is controlled ...
... Jan. 6 Omeros Corporation today announced that The ... grant against milestones to support the Company,s collaboration with ... a new target for the treatment of Parkinson,s disease. ... disease, Omeros is the first to link its novel ...
Cached Biology Technology:Medarex to Present at the 27th Annual J.P. Morgan Healthcare Conference 2Pharmacyclics Secures $5.0 Million in Debt Financing 2Pharmacyclics Secures $5.0 Million in Debt Financing 3Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinson's Disease Target 2Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinson's Disease Target 3
(Date:10/17/2014)... . To date, ... overdoses, doctors are often limited to supportive therapy such as ... combination of drugs involved. So what can be done if ... ETH professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences ... question. "The task was to develop an agent that could ...
(Date:10/16/2014)... Researchers at William and Mary,s Virginia Institute of ... from the Environmental Protection Agency to identify the ... and to develop tools to help local governments ... project depends critically on a dataset of tidal-marsh ... 1970s. Only with this historical baseline can today,s ...
(Date:10/16/2014)... have challenged conventional thinking on how the bowel lining ... for how bowel cancer starts. , The researchers produced ... regenerating the ,crypts, that are a feature of the ... in bowel cancer development, a controversial finding as scientists ... Using 3D imaging technologies, Dr Chin Wee Tan and ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3Cryptic clues drive new theory of bowel cancer development 2
... infectious diseases are urgently needed in resource-limited countries. ... Academy of Microbiology colloquium, "Bringing the Lab to ... Settings," describes the challenges inherent in bringing new ... the world where they are needed most. Point-of-care ...
... team of UC Davis investigators has found that a genetic ... prostate cancer. The mutation of the so-called p53 (or Tp53) ... now has never been shown to act as an initiating ... treating the disease. The study was published online ...
... one of the few probiotics with medical food designation for ... of more than 80 studies that have demonstrated its use ... ileal pouch. Ulcerative colitis patients, in particular, have been shown ... drug regimen. One particular study shows that the combination of ...
Cached Biology News:Report addresses challenges in implementing new diagnostic tests where they are needed most 2UC Davis scientists find new role for P53 genetic mutation -- initiation of prostate cancer 2By adding VSL#3 probiotic to traditional therapies UC patients can improve remission rates 2
Rabbit polyclonal to Quinolinic acid ( Abpromise for all tested applications). Antigen: Synthetic quinolinic acid conjugated to bovine serum albumin....
Human Cell Line Slides...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile...
Mouse Cell Line Slides...
Biology Products: